Nigeria Partners with China to Establish Africa's First Local Insulin Production Facility
Key Insights
Nigeria has signed a memorandum of understanding with China's Shanghai Haiqi Industrial Company Limited (search) to establish what Chinese officials describe as Africa's first local insulin production facility.
The initiative aims to end Nigeria's reliance on imported insulin and position the country as a regional hub for medical biotechnology in West Africa.
The project addresses the exponential growth of diabetes (search) on the continent, which is projected to affect almost 60 million people by 2050 compared to 2.5 million estimated cases in 2000.
Nigeria has entered into a landmark partnership with China to establish a local insulin production facility, marking a significant step toward pharmaceutical self-sufficiency in Africa's most populous nation. The memorandum of understanding between Nigeria's National Biotechnology Research and Development Agency (search) (NBRDA) and Shanghai Haiqi Industrial Company Limited (search) was announced during celebrations for the 76th anniversary of the People's Republic of China.
Chinese Ambassador to Nigeria Yu Dunhai described the initiative as potentially transformative for diabetes (search) management across the region. "Chinese companies are in talks with Nigeria to build Africa's first local insulin production facility, potentially ending Nigeria's reliance on imported insulin and positioning it as a hub for African biotechnology," Yu stated.
Addressing Africa's Growing Diabetes Crisis
The timing of this initiative reflects the urgent need to address diabetes (search) on the African continent. Diabetes cases are increasing exponentially, with projections indicating that almost 60 million people will be affected by 2050 – a dramatic surge from the 2.5 million estimated cases in 2000.
Nigeria's Minister of Innovation, Science and Technology, Uche Nnaji, characterized the agreement as "a landmark moment in Nigeria's scientific and healthcare journey." He emphasized that local production will not only meet critical health needs but also create jobs, develop technical expertise, and establish Nigeria as a regional hub for medical biotechnology.
Technology Transfer and Economic Impact
The partnership promises significant economic benefits through technology transfer and local manufacturing capabilities. "This cooperation will ensure a stable supply of insulin in Nigeria, promote development of the country's pharmaceutical manufacturing capacity through technology transfer and local production, create more jobs, and contribute to economic growth," Nnaji explained.
NBRDA Director-General Mustapha Abdullahi highlighted the broader regional implications of the project. "Insulin is normally imported and comes in different types, but today we are moving towards a standard local production system," Abdullahi said. "This effort is not only for Nigeria but for other African countries as well."
Strategic Partnership Expansion
Nigerian Deputy Senate President Barau Jibrin, represented by Senator Babangida Hussaini, welcomed the project as a symbol of the deepening strategic partnership between Nigeria and China. He noted that cooperation is expanding beyond infrastructure into people-to-people ties, with thousands of young Nigerians now studying in China.
The initiative represents part of Nigeria's broader push to localize essential drug production, which officials expect will reduce costs for patients and enhance the country's position in Africa's pharmaceutical sector. According to Abdullahi, this effort will resolve ongoing challenges in insulin supply while establishing a foundation for sustainable pharmaceutical manufacturing in the region.